Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1119 Results

Title
Intervention Indication Therapeutic Area Year Actions
Semaglutide for treating overweight and obesity in adolescents ages 12 to 17 years old Semaglutide (Ozempic) Obesity Endocrine Nutritional and Metabolic Disorders 2022 View  |  Download
Semaglutide for treating overweight or obesity with cardiovascular disease Semaglutide (Ozempic) Cardiovascular disease (CVD) , Obesity Cardiovascular System , Endocrine Nutritional and Metabolic Disorders 2023 View  |  Download
Semaglutide for treating peripheral arterial disease (PAD) and type 2 diabetes Semaglutide (Ozempic) Peripheral arterial disease (PAD) , Type 2 diabetes Cardiovascular System , Endocrine Nutritional and Metabolic Disorders 2022 View  |  Download
Serplulimab with chemotherapy for treating previously untreated extensive stage small-cell lung cancer Serplulimab (HLX10) Small-cell lung cancer (SCLC) Lung and Respiratory Cancer 2023 View  |  Download
Setmelanotide for obesity in Bardet-Biedl syndrome and Alstrom syndrome Setmelanotide (RM-493) Hyperphagia , Obesity Endocrine Nutritional and Metabolic Disorders , Gastroenterology , Genetic Disorders 2021 View  |  Download
Setmelanotide for pro-opiomelanocortin deficiency obesity Setmelanotide (RM-493) Obesity due to pro-opiomelanocortin deficiency Endocrine Nutritional and Metabolic Disorders 2017 View  |  Download
Setmelanotide for rare genetic obesity due to leptin receptor deficiency Setmelanotide (RM-493) Obesity due to Leptin receptor deficiency Endocrine Nutritional and Metabolic Disorders 2019 View  |  Download
Setmelanotide for treating acquired hypothalamic obesity in people 4 years and older Setmelanotide (RM-493) Hypothalamic obesity Endocrine Nutritional and Metabolic Disorders 2024 View  |  Download
Setmelanotide for treating obesity caused by rare genetic disorders in children aged 2 to 6 years Setmelanotide (RM-493) Obesity Endocrine Nutritional and Metabolic Disorders 2022 View  |  Download
Seviprotimut-L for Malignant Melanoma after Surgery Seviprotimut-L (POL-103A) Melanoma Skin Cancer 2018 View  |  Download
1 2 91 92 93 94 95 111 112
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications